Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eterna Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ERNA
Nasdaq
8731
https://eternatx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eterna Therapeutics Inc
Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors
- Nov 2nd, 2023 3:48 pm
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
- Nov 1st, 2023 12:30 pm
Insider Stock Buying Reaches US$2.7m On Eterna Therapeutics
- Sep 8th, 2023 7:45 pm
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
- Sep 6th, 2023 5:01 pm
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
- Sep 6th, 2023 1:40 pm
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
- Sep 6th, 2023 12:00 pm
Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors
- Sep 5th, 2023 3:24 pm
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
- Sep 5th, 2023 12:30 pm
Eterna Therapeutics Announces $8.7M Private Placement Transaction
- Jul 18th, 2023 6:24 pm
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
- Jul 18th, 2023 12:00 pm
Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors
- Jul 11th, 2023 3:21 pm
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
- Jul 11th, 2023 12:30 pm
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel
- May 24th, 2023 3:18 pm
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
- May 24th, 2023 12:30 pm
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
- May 17th, 2023 12:30 pm
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
- May 4th, 2023 12:30 pm
Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis
- May 3rd, 2023 5:40 pm
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
- May 2nd, 2023 11:30 am
Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million
- Apr 11th, 2023 12:00 pm
Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board
- Mar 28th, 2023 12:30 pm
Scroll